Literature DB >> 18301294

The changing face of the exocrine pancreas in cystic fibrosis: the correlation between pancreatic status, pancreatitis and cystic fibrosis genotype.

Arie Augarten1, Amir Ben Tov, Igal Madgar, Asher Barak, Hanna Akons, Joseph Laufer, Ori Efrati, Micha Aviram, Lea Bentur, Hannah Blau, Gideon Paret, Michael Wilschanski, Bat-Sheva Kerem, Yaakov Yahav.   

Abstract

OBJECTIVES: The aims of this study were to determine the current pancreatic status of the entire cystic fibrosis (CF) population of Israel, to analyze the clinical characteristics of the pancreatic sufficient (PS) patients, and to characterize the correlation between pancreatic status, pancreatitis, and CF genotype.
METHODS: The Israeli CF database includes 505 patients. These patients were defined as being PS or insufficient according to their fecal pancreatic elastase level or by coefficient fat absorption findings. Mutations were categorized as severe (DeltaF508, W1282X, G542X, S549R, N1303K, Q359K/T360K, 405+1G, and 1717) or mild/variable (3849+10 kb, D1152H, G85E, I1234V, R334W, and 5T) based on disease severity in patients carrying these mutations. Age at diagnosis, presenting symptoms, sweat-chloride concentrations, occurrence of pancreatitis, presence of diabetes, and liver disease were recorded.
RESULTS: One hundred and thirty-nine (27.5%) of the CF patients were PS. None carried two mutations associated with severe disease. Over one third (34%) had normal or borderline sweat tests; 20 of these 139 patients had pancreatitis (14.3%) but none of the 366 pancreatic insufficient patients had it. Four initially PS patients became pancreatic insufficient: conversion followed several events of pancreatitis in three of them. Nasal potential differences were all pathological in 35 tested PS patients. None had either diabetes or liver disease.
CONCLUSIONS: A substantial number of CF patients are PS. All of them carry at least one mild mutation enabling production of a sufficient amount of normal mRNA to maintain exocrine pancreatic function. Pancreatitis occurs only in CF patients who are PS. These patients are at risk of progressing to pancreatic insufficiency.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18301294     DOI: 10.1097/MEG.0b013e3282f36d04

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  15 in total

Review 1.  Chronic pancreatitis in India and Asia.

Authors:  Pramod Kumar Garg
Journal:  Curr Gastroenterol Rep       Date:  2012-04

2.  Combined bicarbonate conductance-impairing variants in CFTR and SPINK1 variants are associated with chronic pancreatitis in patients without cystic fibrosis.

Authors:  Alexander Schneider; Jessica Larusch; Xiumei Sun; Amy Aloe; Janette Lamb; Robert Hawes; Peter Cotton; Randall E Brand; Michelle A Anderson; Mary E Money; Peter A Banks; Michele D Lewis; John Baillie; Stuart Sherman; James Disario; Frank R Burton; Timothy B Gardner; Stephen T Amann; Andres Gelrud; Ryan George; Matthew J Rockacy; Sirvart Kassabian; Jeremy Martinson; Adam Slivka; Dhiraj Yadav; Nevin Oruc; M Michael Barmada; Raymond Frizzell; David C Whitcomb
Journal:  Gastroenterology       Date:  2010-10-25       Impact factor: 22.682

3.  Validity and Reliability of a Novel Multimodal Questionnaire for the Assessment of Abdominal Symptoms in People with Cystic Fibrosis (CFAbd-Score).

Authors:  Anke Jaudszus; Elisa Zeman; Tatjana Jans; Elena Pfeifer; Harold Tabori; Christin Arnold; Ruth K Michl; Michael Lorenz; Natalie Beiersdorf; Jochen G Mainz
Journal:  Patient       Date:  2019-08       Impact factor: 3.883

4.  Cystic fibrosis mutations for p.F508del compound heterozygotes predict sweat chloride levels and pancreatic sufficiency.

Authors:  R Sebro; H Levy; K Schneck; D Dimmock; B A Raby; C L Cannon; U Broeckel; N J Risch
Journal:  Clin Genet       Date:  2011-11-29       Impact factor: 4.438

Review 5.  Subject review: pancreatic ductal adenocarcinoma in the setting of mutations in the cystic fibrosis transmembrane conductance regulator gene: case report and review of the literature.

Authors:  David W Rittenhouse; Vanessa A Talbott; Zafia Anklesaria; Jonathan R Brody; Agneszkia K Witkiewicz; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2011-08-02       Impact factor: 3.452

Review 6.  Animal models of gastrointestinal and liver diseases. Animal models of cystic fibrosis: gastrointestinal, pancreatic, and hepatobiliary disease and pathophysiology.

Authors:  Alicia K Olivier; Katherine N Gibson-Corley; David K Meyerholz
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-01-15       Impact factor: 4.052

Review 7.  Pancreatic pathophysiology in cystic fibrosis.

Authors:  Katherine N Gibson-Corley; David K Meyerholz; John F Engelhardt
Journal:  J Pathol       Date:  2015-10-01       Impact factor: 7.996

Review 8.  Cystic fibrosis from the gastroenterologist's perspective.

Authors:  Chee Y Ooi; Peter R Durie
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-01-21       Impact factor: 46.802

9.  Cystic Fibrosis Related Diabetes: a Unique Challenge in Diabetes Care.

Authors:  Marina Litvin; Schola Nwachukwu
Journal:  Mo Med       Date:  2016 Sep-Oct

10.  Early acute pancreatitis in a child with compound heterozygosis ∆F508/R1438W/Y1032C cystic fibrosis: a case report.

Authors:  Salvatore Leonardi; Andrea Domenico Praticò; Novella Rotolo; Giovanna Di Dio; Elena Lionetti; Mario La Rosa
Journal:  J Med Case Rep       Date:  2013-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.